TrustFinance is trustworthy and accurate information you can rely on. If you are looking for financial business information, this is the place for you. All-in-One source for financial business information. Our priority is our reliability.

TrustFinance Global Insights
Mar 03, 2026
2 min read
32

Medline Industries Inc. (NYSE:MDLN) shares dropped 4.4% to $43.84 in premarket trading following the company's announcement of a 75 million share secondary offering by its major stockholders.
The selling stockholders include prominent investment firms Blackstone Inc., Carlyle Group Inc., and Hellman & Friedman, each offering 23.3 million shares. The Abu Dhabi Investment Authority is also selling approximately 5.1 million shares. The offering is being managed by global coordinators including Goldman Sachs, Morgan Stanley, BofA Securities, and J.P. Morgan.
An increase in the supply of shares from a secondary offering typically puts downward pressure on a stock's price. This move allows early investors to capitalize on their investment in the company, which executed one of the largest initial public offerings in recent years. According to the prospectus, Medline has 1.31 billion shares outstanding.
Market participants will now closely watch the pricing of the secondary offering and the stock's subsequent trading activity. The sale by foundational investors is a significant event that will influence Medline's stock performance in the near term.
Q: Why did Medline's stock price fall?
A: The stock price fell after the announcement of a large secondary offering of 75 million shares, which increases the public supply of the stock.
Q: Who is selling Medline shares?
A: The shares are being sold by major institutional investors, including Blackstone, Carlyle Group, Hellman & Friedman, and the Abu Dhabi Investment Authority.
Source: Investing.com

TrustFinance Global Insights
AI-assisted editorial team by TrustFinance curating reliable financial and economic news from verified global sources.
Related Articles